Fig. 5From: Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcomaInhibitory effect of TAS-115 and pazopanib on c-MET, PDGFRα and their downstream effectors in vivo. a, b Mice bearing Yamato-SS (c-MET-dependent) cells and mice bearing SYO-1 (PDGFRα-dependent) SS cells were treated with orally administered TAS-115 (200 mg/kg) or pazopanib (100 mg/kg) or control for consecutive 3 days and euthanized 3 h after the final administrationBack to article page